Janux Therapeutics, Inc. (JANX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$16.66-2.34%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Janux Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	7.29M
EPS	—	-0.533
Annual ending 2026-12-31
Revenue	—	30.07M
EPS	—	-1.746
Annual ending 2027-12-31
Revenue	—	8.72M
EPS	—	-2.674

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improvement in cash from operating activities	Cash flow improved from -$28.54M to -$12.34M in one quarter.	Improving	Cash flow worsens beyond -$12.34M in next 4 quarters	Cash from operations: $12.484M FY2026-Q2; GAAP. Published target: Cash from operations improves to better than -$12.34M. Target period is not explicitly aligned with this observation. Source published Aug 6, 202612,484,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Move toward positive earnings results	A primary condition in Janux Therapeutics, Inc.'s published investment case. The stated target is Earnings loss narrows from -$1.76 FY26 toward break-even.	Under Pressure	EPS loss worsens beyond -$1.76 in FY26	Diluted EPS: $-0.35 per share FY2026-Q2; GAAP. Published target: Earnings loss narrows from -$1.76 FY26 toward break-even. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.35 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e0959438-c0bb-421a-9946-622ac272142a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Progress in developing and commercializing therapy with Bristol-Myers Squibb	Janux works with Bristol-Myers Squibb on a new cancer therapy.	Intact	Partnership progress stalls or ends before FY26	Qualitative: BMS partnership active (Jan 2026) Jan 2026 exclusive license agreement with BMS for tumor-activated therapeutic. No negative partnership news reported. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.67

$-2.70 → $-2.67 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.70	$6,952,140	13 / 14
2026-07-25	$-2.68	$6,978,571	12 / 10
2026-07-26	$-2.70	$6,952,140	13 / 14
2026-07-27	$-2.68	$6,978,571	12 / 10
2026-07-28	$-2.70	$6,952,140	13 / 14
2026-07-29	$-2.70	$6,952,140	13 / 14
2026-07-30	$-2.70	$6,952,140	13 / 14
2026-07-31	$-2.70	$6,952,140	13 / 14
2026-08-01	$-2.68	$6,978,571	12 / 10
2026-08-02	$-2.70	$6,952,140	13 / 14
2026-08-03	$-2.70	$6,952,140	13 / 14
2026-08-04	$-2.70	$6,952,140	13 / 14
2026-08-05	$-2.70	$6,952,140	13 / 14
2026-08-06	$-2.68	$6,978,571	12 / 10
2026-08-07	$-2.68	$6,978,571	12 / 10
2026-08-08	$-2.70	$7,486,920	13 / 13
2026-08-09	$-2.70	$7,486,920	13 / 13
2026-08-10	$-2.68	$6,978,571	12 / 10
2026-08-12	$-2.68	$6,978,571	12 / 10
2026-08-13	$-2.68	$6,978,571	12 / 10
2026-08-14	$-2.68	$6,978,571	12 / 10
2026-08-15	$-2.68	$6,978,571	12 / 9
2026-08-16	$-2.68	$6,978,571	12 / 9
2026-08-17	$-2.68	$6,978,571	12 / 9
2026-08-18	$-2.68	$6,978,571	12 / 10
2026-08-19	$-2.68	$6,978,571	12 / 10
2026-08-20	$-2.67	$8,716,538	11 / 10
2026-08-21	$-2.67	$8,716,538	11 / 10
2026-08-22	$-2.67	$8,716,538	11 / 10
2026-08-23	$-2.67	$8,716,538	11 / 10
2026-08-24	$-2.67	$8,716,538	11 / 10
2026-08-25	$-2.67	$8,716,538	12 / 10
2026-08-26	$-2.67	$8,716,538	12 / 10
2026-08-27	$-2.67	$8,716,538	12 / 10
2026-08-28	$-2.67	$8,716,538	12 / 10
2026-08-29	$-2.67	$8,716,538	12 / 10
2026-08-30	$-2.67	$8,716,538	12 / 10
2026-08-31	$-2.67	$8,716,538	12 / 10
2026-09-01	$-2.67	$8,716,538	12 / 10
2026-09-02	$-2.67	$8,716,538	12 / 10
2026-09-03	$-2.67	$8,716,538	12 / 10
2026-09-04	$-2.67	$8,716,538	12 / 10
2026-09-05	$-2.67	$8,716,538	12 / 10
2026-09-06	$-2.67	$8,716,538	12 / 10
2026-09-07	$-2.67	$8,716,538	12 / 10
2026-09-08	$-2.67	$8,716,538	12 / 10
2026-09-09	$-2.67	$8,716,538	12 / 10
2026-09-10	$-2.67	$8,716,538	12 / 10
2026-09-11	$-2.67	$8,716,538	12 / 10
2026-09-12	$-2.67	$8,716,538	12 / 10
2026-09-13	$-2.67	$8,716,538	12 / 10
2026-09-14	$-2.67	$8,716,538	12 / 10
2026-09-15	$-2.67	$8,716,538	12 / 10
2026-09-16	$-2.67	$8,716,538	12 / 10
2026-09-17	$-2.67	$8,716,538	12 / 10
2026-09-18	$-2.67	$8,716,538	12 / 10
2026-09-19	$-2.67	$8,716,538	12 / 10
2026-09-20	$-2.67	$8,716,538	12 / 10
2026-09-21	$-2.67	$8,716,538	12 / 10
2026-09-22	$-2.67	$8,716,538	12 / 10
2026-09-23	$-2.67	$8,716,538	12 / 10
2026-09-24	$-2.67	$8,716,538	12 / 10
2026-09-25	$-2.67	$8,716,538	12 / 10
2026-09-26	$-2.67	$8,716,538	12 / 10
2026-09-27	$-2.67	$8,716,538	12 / 10
2026-09-28	$-2.67	$8,716,538	12 / 10
2026-09-29	$-2.67	$8,716,538	12 / 10
2026-09-30	$-2.67	$8,716,538	12 / 10
2026-10-01	$-2.67	$8,716,538	12 / 10
2026-10-02	$-2.67	$8,716,538	12 / 10
2026-10-03	$-2.67	$8,716,538	12 / 10
2026-10-04	$-2.67	$8,716,538	12 / 10
2026-10-05	$-2.67	$8,716,538	12 / 10
2026-10-06	$-2.67	$8,716,538	12 / 10
2026-10-07	$-2.67	$8,716,538	12 / 10
2026-10-08	$-2.67	$8,716,538	12 / 10
2026-10-09	$-2.67	$8,716,538	12 / 10
2026-10-10	$-2.67	$8,716,538	12 / 10
2026-10-11	$-2.67	$8,716,538	12 / 10
2026-10-12	$-2.67	$8,716,538	12 / 10
2026-10-13	$-2.67	$8,716,538	12 / 10
2026-10-14	$-2.67	$8,716,538	12 / 10
2026-10-15	$-2.67	$8,716,538	12 / 10
2026-10-16	$-2.67	$8,716,538	12 / 10
2026-10-17	$-2.67	$8,716,538	12 / 10
2026-10-18	$-2.67	$8,716,538	12 / 10
2026-10-19	$-2.67	$8,716,538	12 / 10
2026-10-20	$-2.67	$8,716,538	12 / 10
2026-10-21	$-2.67	$8,716,538	12 / 10
2026-10-22	$-2.67	$8,716,538	12 / 10
2026-10-23	$-2.67	$8,716,538	12 / 10
2026-10-24	$-2.67	$8,716,538	12 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	15	2	1
2026-06-01	15	2	1
2026-07-01	15	2	1
2026-08-01	16	2	1
2026-09-01	16	1	1
2026-10-01	16	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improvement in cash from operating activitiesCash from operations: $12.484M
Move toward positive earnings resultsPublished status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-64.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Janux Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

JANX is a speculative clinical-stage biotechnology company, meaning its business case depends on developing treatments that are still being tested. Its long-term thesis is in a watch state: management is advancing the pipeline, while recent financial performance is below its industry cohort and the company remains loss-making.

What's priced into Janux Therapeutics, Inc.

The valuation model shows JANX at a 4.78 premium versus peers, with optionality, or potential value from future pipeline success, driving the gap. The expectations gap is 0.36, but model confidence is low, so the degree of optimism already reflected in valuation is uncertain.

What the fundamentals likely do

Near term, continued clinical enrollment and planned initiation of JANX013 support pipeline progress, while stable cash near $970 million provides funding for development. Research and development spending rose modestly in the latest quarter, and a recent earnings miss plus a high-miss-rate industry make the next results worth watching.

What Janux Therapeutics, Inc. hinges on

Over the multi-year view, the central swing factor is whether clinical programs advance while management maintains enough cash to support them. Near term, weakening jobs data could increase recession concerns, while results and guidance from healthcare peers could either reinforce or weaken the sector tailwind.